{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:08:48Z","timestamp":1790795328388,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.lungcan.2016.11.023","type":"journal-article","created":{"date-parts":[[2016,12,5]],"date-time":"2016-12-05T02:00:42Z","timestamp":1480903242000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":160,"special_numbering":"C","title":["High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer"],"prefix":"10.1016","volume":"104","author":[{"given":"Yusuke","family":"Okuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kageaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Sagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadamu","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2016.11.023_bib0005","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1378\/chest.08-0978","article-title":"The new lung cancer staging system","volume":"136","author":"Detterbeck","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0010","doi-asserted-by":"crossref","unstructured":"N.J. Petrelli, E.P. Winer, J. Brahmer, S. Dubey, S. Smith, C. Thomas, L.T. Vahdat, J. Obel, N. Vogelzang, M. Markman, J.W. Sweetenham, D. Pfister, M.G. Kris, L.M. Schuchter, R. Sawaya, D. Raghavan, P.A. Ganz, B. Kramer, Clinical Cancer Advances 2009 major research advances in cancer treatment, prevention, and screening\u2013a report from the American Society of Clinical Oncology. J. Clin. Oncol., 2009. 27, 6052\u20136069.","DOI":"10.1200\/JCO.2009.26.6171"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0015","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.molmed.2015.05.005","article-title":"Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system","volume":"21","author":"Pico de Coana","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0020","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1078-0432.CCR-12-2063","article-title":"Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer","volume":"19","author":"Sznol","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0030","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0035","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Investigators K-: Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0040","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","volume":"41","author":"Meng","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0045","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.jtho.2016.02.015","article-title":"Predictive markers for the efficacy of anti-PD-1\/PD-L1 antibodies in lung cancer","volume":"11","author":"Shukuya","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl. (3)","key":"10.1016\/j.lungcan.2016.11.023_bib0050","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.seminoncol.2015.10.002","article-title":"Immunotherapy combinations with checkpoint inhibitors in metastatic melanoma: current approaches and future directions","volume":"42","author":"Atkins","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0055","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","article-title":"Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma","volume":"17","author":"Frigola","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0060","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0065","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target","volume":"101","author":"Thompson","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0070","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0075","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/1759-7714.12247","article-title":"Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics","volume":"6","author":"Zhang","year":"2015","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0080","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","article-title":"Statistics Subcommittee of the NCIEWGoCD. REporting recommendations for tumour MARKer prognostic studies (REMARK)","volume":"93","author":"McShane","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cyto.2011.06.004","article-title":"Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines","volume":"56","author":"Chen","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0090","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1016\/j.febslet.2012.07.032","article-title":"Immunoregulatory molecules are master regulators of inflammation during the immune response","volume":"586","author":"de la Fuente","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/03009742.2013.823517","article-title":"Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis","volume":"43","author":"Greisen","year":"2014","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2015.12.006","article-title":"PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors","volume":"93","author":"Meniawy","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0110","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.imlet.2011.11.001","article-title":"Soluble B7-H1: differences in production between dendritic cells and T cells","volume":"142","author":"Frigola","year":"2012","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0115","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bjc.2014.555","article-title":"PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients","volume":"112","author":"D'Incecco","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0120","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.5301\/jbm.5000170","article-title":"PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer","volume":"30","author":"Cheng","year":"2015","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-13-0539","article-title":"Smoking, p53 mutation, and lung cancer","volume":"12","author":"Gibbons","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0130","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1158\/1078-0432.CCR-14-3175","article-title":"Cancer neoantigens and applications for immunotherapy","volume":"22","author":"Desrichard","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0140","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0145","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0150","doi-asserted-by":"crossref","first-page":"29794","DOI":"10.18632\/oncotarget.7631","article-title":"The effect of chemotherapy on programmed cell death 1\/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response","volume":"7","author":"Luo","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0155","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.29889","article-title":"Irradiation and immunotherapy: from concept to the clinic","volume":"122","author":"Salama","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0160","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","article-title":"PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction","volume":"19","author":"Abiko","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0165","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1093\/annonc\/mdu452","article-title":"PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics","volume":"25","author":"Massi","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0170","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/labinvest.2013.130","article-title":"Programmed death ligand-1 expression in non-small cell lung cancer","volume":"94","author":"Velcheti","year":"2014","journal-title":"Lab. Investig."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0175","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejca.2015.12.033","article-title":"Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma","volume":"57","author":"Yang","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2016.11.023_bib0180","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2009.07.013","article-title":"Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients","volume":"52","author":"Chew","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0185","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/1078-0432.CCR-15-1543","article-title":"Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma","volume":"22","author":"Vassilakopoulou","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2016.11.023_bib0190","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2016.08.001","article-title":"Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib","volume":"100","author":"Sorensen","year":"2016","journal-title":"Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216305396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500216305396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T03:01:12Z","timestamp":1568602872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500216305396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":38,"alternative-id":["S0169500216305396"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.11.023","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2016.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}